25 C
Nairobi
Wednesday, January 22, 2025

 The Top 20 Richest Women In Africa 2020

Gone are the days when a woman's place was the kitchen. Africa has seen a new breed of women who are not afraid to...

Barron Trump: Profile of Donald Trump’s 18-Year-Old Son Who Pushed Him to Victory

Donald Trump is back in the White House, clinching the presidency of the United States for the second time in a stunning comeback.  His...
HomenewsGovernment Issues Recall for H.Pylori and Ulcer Drug Over Packaging Mistake

Government Issues Recall for H.Pylori and Ulcer Drug Over Packaging Mistake

JOIN WOK ON TELEGRAM

The Pharmacy and Poisons Board (PPB) of Kenya has issued a public alert recalling popular drug ,S-PRAZO (Esomeprazole Magnesium Delayed-Release Capsules 40mg), Batch No SPZ-302, manufactured by Laborate Pharmaceutical India Limited.

The drug which is primarily used for the treatment of infections caused by the H. pylori bacteria among other stomach acidity conditions, was recalled following complaints by Kenyans who reported a packaging mix-up alongside another drug, Donystatin, contained in the same carton.

“The product batch is being recalled following a market complaint regarding mix-up of blister strips; some boxes were found to contain two different blister strips, i.e. S-Prazo Capsules and Donystatin Tablets, within the same outer carton,” stated the PPB.

See also  Fertiliser Scandal: More Than 560 Tonnes of Donated Fertiliser Goes Missing

S-PRAZO, a proton pump inhibitor, treats GERD (Gastroesophageal Reflux Disease), prevents NSAID-related gastric ulcers, eradicates H. pylori, and manages conditions with excessive gastric acid. Donystatin on the other hand is a polyene antifungal which targets cutaneous, mucocutaneous, and gastrointestinal fungal infections, especially those caused by Candida species.

Accidentally packaging another medication together could lead to serious health risks for patients, including incorrect dosing or harmful reactions mostly altering stomach acidity.

The Board has ordered all pharmaceutical outlets, healthcare providers, and the public to halt the distribution, sale, and use of the affected batch immediately. Anyone who has purchased or still has the drug was urged to return it to the nearest healthcare facility or supplier.

See also  Mung Beans Bill 2022: Unlicensed Ndengu Farmers To Face Kshs 1M Fine In New Proposal

“The board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to stop any further distribution, sale, issuance, or use of the product batch and return it to their nearest healthcare facility or respective suppliers,” it added.

The Pharmacy and Poisons Board additionally urged the public to report any suspected substandard medicines or adverse reactions through its official communication channels.

The board has also assured Kenyans that they are taking comprehensive steps to resolve the issue and prevent any future occurrences.

“The Pharmacy and Poisons Board is dedicated to protecting the public against sub-standard drugs,” the board stated.